Short Interest Update on EXACT Sciences Corporation (EXAS)

EXACT Sciences Corporation (EXAS) has 24,776,205 shares of shorts outstanding as on August 15, 2016, with 5 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 33,346,402 shares. The stock has a decent trading volume of 4,584,143 shares daily. The marginal decrease in the short positions is by -25.7%, which amounts to -8,570,197 shares. Short positions are 25.9% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.

EXACT Sciences Corporation (NASDAQ:EXAS): The stock opened at $20.34 on Wednesday but the bulls could not build on the opening and the stock topped out at $20.41 for the day. The stock traded down to $18.58 during the day, due to lack of any buying support eventually closed down at $18.97 with a loss of -7.15% for the day. The stock had closed at $20.43 on the previous day. The total traded volume was 4,336,583 shares.


In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Exact Sciences Corp, Zanotti Katherine S, had purchased 3,380 shares in a transaction dated on August 3, 2016. The transaction was executed at $17.93 per share with total amount equaling $60,603.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.